{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["31(8)"],"submitter":["Preusser M"],"funding":["Daiichi Sankyo Company"],"pubmed_abstract":["Leptomeningeal metastatic disease (LMD) is a severe complication of solid cancers with poor outcomes and limited treatment options. The antibody-drug conjugate patritumab deruxtecan (HER3-DXd) demonstrated efficacy in breast and lung cancers, and HER3 is involved in central nervous system metastases, particularly in parenchymal colonization. In this study, we investigated HER3-DXd efficacy and safety in patients with LMD in cohort 3 of the TUXEDO-3 phase 2 trial. Key eligibility criteria included age ≥18 years, treatment-naive LMD or LMD progressing after radiotherapy from any solid tumor and Eastern Cooperative Oncology Group performance status of 0-2. Between January and July 2024, 20 evaluable patients (nine with type I and 11 with type II LMD) were accrued and received HER3-DXd 5.6 mg "],"journal":["Nature medicine"],"pagination":["2797-2805"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12353872"],"repository":["biostudies-literature"],"pubmed_title":["Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial."],"pmcid":["PMC12353872"],"pubmed_authors":["Vaz-Batista M","Furtner J","Gonzalez-Alonso P","Oberndorfer F","Jimenez-Cortegana C","Greil R","Arumi M","Llombart-Cussac A","Gion M","Campolier M","Ruiz-Borrego M","Guerrero JA","Preusser M","Berghoff AS","Garcia-Mosquera JJ","Garde-Noguera J","Rodriguez-Morato J","Cortes J","Bartsch R","Marhold M","Fuereder T","Valero M"],"additional_accession":[]},"is_claimable":false,"name":"Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.","description":"Leptomeningeal metastatic disease (LMD) is a severe complication of solid cancers with poor outcomes and limited treatment options. The antibody-drug conjugate patritumab deruxtecan (HER3-DXd) demonstrated efficacy in breast and lung cancers, and HER3 is involved in central nervous system metastases, particularly in parenchymal colonization. In this study, we investigated HER3-DXd efficacy and safety in patients with LMD in cohort 3 of the TUXEDO-3 phase 2 trial. Key eligibility criteria included age ≥18 years, treatment-naive LMD or LMD progressing after radiotherapy from any solid tumor and Eastern Cooperative Oncology Group performance status of 0-2. Between January and July 2024, 20 evaluable patients (nine with type I and 11 with type II LMD) were accrued and received HER3-DXd 5.6 mg ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-29T15:16:18.396Z","creation":"2026-04-08T05:08:16.105Z"},"accession":"S-EPMC12353872","cross_references":{"pubmed":["40447851"],"doi":["10.1038/s41591-025-03744-1"]}}